Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420043 | PMC |
| http://dx.doi.org/10.1016/j.hrcr.2016.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of bivalirudin anticoagulation therapy in adult patients receiving extracorporeal membrane oxygenation: A systematic review and meta-analysis.
Medicine (Baltimore)
August 2025
Emergency Department, Shenzhen Longgang Second People's Hospital, Shenzhen, Guangdong Province, China.
Background: Compared to heparin, there is limited evidence of the benefits of bivalirudin in the patients with extracorporeal membrane oxygenation (ECMO).
Methods: We searched for studies comparing bivalirudin anticoagulation with heparin anticoagulation in ECMO patients in the PubMed, Embase, and Cochrane Library databases from inception to March 28, 2024. ECMO patients were divided into the bivalirudin experimental group and the heparin control group.
Analysis of inter-hospital transfer on clinical outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A secondary analysis of the BRIGHT-4 trial.
PLoS Med
July 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Background: Previous studies evaluating the influence of inter-hospital transfer on mortality in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) reported conflicting results. The multicenter BRIGHT-4 trial demonstrated that bivalirudin plus a post-PCI high-dose infusion (1.75 mg/kg/h) reduced the 30-day primary endpoint of all-cause mortality or Bleeding Academic Research Consortium (BARC) types 3-5 bleeding compared with heparin monotherapy in STEMI patients.
View Article and Find Full Text PDFSuccessful use of bivalirudin in neonates for postoperative aortopulmonary shunt thrombosis prevention.
JTCVS Tech
June 2025
Division of Cardiology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colo.
Objectives: We aim to describe the successful use of bivalirudin for immediate postoperative aortopulmonary shunt thrombosis prevention. This article also describes the details of an institutional protocol for postoperative aortopulmonary shunt thrombosis prevention. In addition, we demonstrate the safe and effective use of low-molecular-weight heparin and aspirin for interstage thrombosis prevention.
View Article and Find Full Text PDFSuccessful pediatric heart transplantation with bivalirudin use in a cyanotic single ventricle patient with an intracorporeal continuous flow ventricular assist device and heparin-induced thrombocytopenia.
Indian J Thorac Cardiovasc Surg
July 2025
Division of Pediatric Cardiothoracic Surgery, University of Miami, Miami, USA FL.
We describe a case of profound coagulopathy during orthotopic heart transplantation in a cyanotic single ventricle pediatric patient with an intracorporeal continuous flow ventricular assist device performed on bivalirudin for heparin-induced thrombocytopenia. This was successfully managed with central veno-arterial extracorporeal membrane oxygenation and hemofiltration as an adjunct to treat bivalirudin-induced coagulopathy due to lack of a reversal agent for bivalirudin.
View Article and Find Full Text PDFTicagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial.
Cardiovasc Revasc Med
May 2025
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background And Aims: The optimal antiplatelet agent regimen in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI) with bivalirudin anticoagulation is uncertain. This analysis sought to evaluate the safety and efficacy of ticagrelor compared with clopidogrel in patients with STEMI treated with PPCI with radial artery access and bivalirudin anticoagulation.
Methods: This post-hoc analysis compared bivalirudin plus ticagrelor with bivalirudin plus clopidogrel in 3009 BRIGHT-4 patients that were treated with PPCI.